SCHEMBL6747710

SCHEMBL6747710

CC1Cc2cc(C(=O)CCl)ccc2NC1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.44
EPHX2 P34913 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.38
NEK2 P51955 4/20 0.38
CDK1 P06493 2/20 0.38
CCNB1 P14635 2/20 0.38
SMYD3 Q9H7B4 5/20 0.38
RAF1 P04049 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
HPGD P15428 1/20 0.36
PYGL P06737 1/20 0.36
PYGM P11217 1/20 0.36
GRIN2B Q13224 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6219159 0.90 EPHX2 (0.40) ALDH1A1MAPTEPHX2SMYD3HPGD
SCHEMBL17713638 0.86 EPHX2 (0.39) MAPTEPHX2SMN1; SMN2SMYD3MEN1
SCHEMBL31544220 0.80 ALOX15 (0.50) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL31544153 0.80 ALOX15 (0.50) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL7434105 0.76 PGR (0.48) ALDH1A1MAPTSMN1; SMN2KDM4ENEK2
SCHEMBL6287035 0.76 ALDH1A1 (0.50) ALDH1A1MAPTEPHX2SMN1; SMN2KDM4E
SCHEMBL9367565 0.76 ALDH1A1 (0.50) ALDH1A1MAPTEPHX2SMN1; SMN2KDM4E
SCHEMBL9366168 0.76 ALDH1A1 (0.50) ALDH1A1MAPTEPHX2SMN1; SMN2KDM4E
SCHEMBL1304506 0.76 EPHX2 (0.59) ALDH1A1MAPTEPHX2SMYD3GRIN2B
SCHEMBL24726554 0.75 SMYD3 (0.38) ALDH1A1MAPTEPHX2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia ANDREANA TONJA LYNN (US) 2004-07-15 US disclosed
EP-0409435-B1 Heteroaryl piperazine antipsychotic agents PFIZER (US) 1994-10-26 EP disclosed
US-5350747-A Heteroaryl piperazine antipsychotic agents PFIZER INC (US) 1994-09-27 US disclosed
WO-1991000863-A1 HETEROARYL PIPERAZINE ANTIPSYCHOTIC AGENTS PFIZER INC. (US) 1991-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138230-A1 Heterocyclic substituted piperazines for the treatment of schizophrenia CNR1, DRD2, CNR2 ALDH1A1 460/4885MAPT 2926/4885EPHX2 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.